Abstract
Recent in vitro studies have identified small-molecule pharmaceuticals effecting dose-dependent changes in the mammalian circadian clock, providing a novel avenue for control. Most studies employ light for clock control, however, pharmaceuticals are advantageous for clock manipulation through reduced invasiveness. In this paper, we employ a mechanistic model to predict the phase dynamics of the mammalian circadian oscillator under the effect of the pharmaceutical under investigation. These predictions are used to inform a constrained model predictive controller (MPC) to compute appropriate dosing for clock re-entrainment. Constraints in the formulation of the MPC problem arise from variation in the phase response curves (PRCs) describing drug effects, and are in many cases non-intuitive owing to the nonlinearity of oscillator phase response effects. We demonstrate through in-silico experiments that it is imperative to tune the MPC parameters based on the drug-specific PRC for optimal phase manipulation.